Increased Scheme Consideration from Pfizer • ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: - A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or - A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration) • Relative to ResApp’s share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: - 130.0% based on the Confirmed Data Consideration - 62.2% based on the Unconfirmed Data Consideration • Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders • The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme
- Forums
- ASX - By Stock
- RAP
- Ann: Increased Scheme Consideration from Pfizer
Ann: Increased Scheme Consideration from Pfizer, page-4
-
- There are more pages in this discussion • 374 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online